2- Tuesday Pharmacy Practice News – 10th August

1 – Pharmacy leaders discuss the future of telehealth at virtual PELA® conference

• ASHP’s second Pharmacy Executive Leadership Alliance (PELA®) virtual conference, held May 11, welcomed pharmacy executives from across the country to share views and learn from experts about the emerging role of telehealth technology in US healthcare.
• McClellan, a past chief of the Centers for Medicare & Medicaid Services and the Food and Drug Administration, described how telehealth has become invaluable to patient care—especially at the start of the COVID-19 pandemic.

Source: Oxford Academic

2 – Pharmacists promote COVID-19 vaccine acceptance in rural locales

• What data support the effectiveness of COVID-19 vaccines against emerging variant strains? When can children under age 16 years get vaccinated? Should I get vaccinated if I need allergy shots?
• Those were some of the questions listeners had for Sarah Pagenkopf, director of pharmacy for Fort HealthCare.
• According to the Centers for Disease Control and Prevention (CDC), unfounded fears about COVID-19 immunization include myths that the vaccines impair fertility, alter the recipient’s DNA, and cause COVID-19, and that vaccinated people shed virus that can harm those around them.
• Pharmacy has been in the thick of the pandemic response for months.
• Pharmacy staff helped to prepare registration information for COVID-19 vaccinations and coordinated the health system’s education and training on vaccine storage, handling, and compliance with emergency use authorizations.

Source: Oxford Academic

3 – Decision-making framework for an acute care clinical pharmacist productivity model: Part 1

• Clinical pharmacist productivity assessment has long been challenging, as a standard definition does not exist.
• A multistep project was undertaken with the intent to develop, validate, and implement an acute care clinical pharmacist productivity model.
• The initial step of the project was designed to identify, define, prioritize, and weight a comprehensive list of daily pharmacist responsibilities stratified by relative time spent on each function via consensus.
• The development of an acute care clinical pharmacist productivity model first requires the selection of appropriate work outputs and weighting.
• The consensus process provided a newly identified comprehensive list of pharmacist responsibilities that will serve as the foundation of the clinical productivity model.
• Validated consensus methodology can be useful for engaging clinical pharmacists in decision-making and the development of a clinical productivity model.

Source: Oxford Academic

4- Clinical impact of pharmacist-led antibiotic stewardship programs in outpatient settings in the United States: A scoping review

• This study aims to provide an overview of the impact of pharmacist interventions on antibiotic prescribing and the resultant clinical outcomes in an outpatient antibiotic stewardship program (ASP) in the United States.
• The findings suggest a need for a consistent approach for the practical application of outpatient pharmacist-led ASPs.
• Managed care organizations could play a significant role in ensuring the successful implementation of pharmacist-led ASPs in outpatient settings.

Source: Oxford Academic

5 – A pharmacist-driven Food and Drug Administration incident surveillance and response program for compounded drugs

• This study aims to provide an overview of compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and to describe the pharmacist’s role within the US Food and Drug Administration’s (FDA’s) Compounding Incidents Program, whose efforts are aimed at protecting the public against poor-quality compounded drugs through surveillance, review and response to adverse events and complaints.
• As FDA continues to expand the Compounding Incidents Program and its efforts to protect the public against poor-quality compounded drugs, we encourage the continued submission of adverse event reports by healthcare professionals and consumers to FDA’s MedWatch reporting system in addition to adverse event reporting compliance by outsourcing facilities.

Source: Oxford Academic

 6 – FDA Approves IV Therapy for Adults With Pulmonary Arterial Hypertension

• Officials with the FDA have approved selexipag (Uptravi; Janssen) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class II–III, who are temporarily unable to take oral therapy.
• Selexipag is a selective prostacyclin IP receptor agonist indicated for the treatment of PAH.
• The new FDA approval for selexipag is based on the findings from a prospective, multicenter, open-label single sequence crossover phase 3 study (NCT03187678)designed to assess the safety, tolerability, and pharmacokinetics of temporarily switching between selexipag tablets and selexipag IV.

Source: Pharmacy Times

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2020 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacy Practice FNN E-News, for publication of:

Read & Download FNN Issue 8 of April 2020 FNN News